Vlad Hogenhuis, MD

Chief Business Officer
Vaxanix
(Moderator)

Vlad Hogenhuis, MD, is Chief Business Officer of Vaxanix, a new commercial-stage Oncology company featuring a novel apheresis device approved in Europe to treat various late stage cancers, a squamous cell cancer therapeutic vaccine in late stage development, and a deep pipeline of cell and immuno therapy agents. Prior to joining Vaxanix, Vlad was President and CEO of Chimera Bioengineering and brings more than 28 years of experience in oncology, immunology, and specialty pharma. Prior functions of Vlad include Chief Business Officer for GATT Technologies B.V., a private medtech company in the Netherlands developing novel surgical hemostats, acquired by Ethicon (Johnson & Johnson) in a private transaction. Prior to that, Vlad was Chief Operating Officer of Ultragenyx with responsibilities for global commercial operations, business development, and manufacturing. Before that, Dr. Hogenhuis served as Senior Vice President and Global Franchise Head, where he oversaw Oncology and Immunology. Prior to GSK, he served in leadership positions at Merck & Co. in the US, China, and Europe, where he was responsible for Specialty medicines.

Before his roles in industry, Dr. Hogenhuis was a NIH Fellow at New England Medical Centre in Boston and a Naval Lieutenant Surgeon in the Royal Dutch Navy. Dr. Hogenhuis currently serves on the board of Rezolute Bio (Nasdaq: RZLT), a public biotech company specializing in metabolic diseases. He previously served as a member of the Board of Directors of Vision 2020, a program of the World Health Organization for the prevention of blindness, and on the board of GATT technologies. Dr. Hogenhuis received a M.D. degree in Medicine Cum Laude from the University of Leiden in the Netherlands. He received an MBA from The Wharton School of the University of Pennsylvania.